Printer friendly
"AcronymAttic.com

What does MVP stand for?

MVP stands for mitomycin-C-vindesine-platinum

Advertisement:

This definition appears rarely

See other definitions of MVP

Other Resources: Acronym Finder has 66 verified definitions for MVP

Samples in periodicals archive:

Purpose. In the pioneer data from the Memorial-Sloan-Kettering group, preoperative mitomycin-C-vindesine--platinum (MVP) induction chemotherapy in N2-NSCLC was accompanied with substantial pulmonary toxicity. In this study, the efficacy and toxicity of three-drug VIP induction chemotherapy, the pathologic response in resection specimens, the early survival and relapse patterns are examined. Patients and methods: Between June 1995 and March 1997, 39 consecutive patients with pathology proven N2-NSCLC were treated with three cycles of VIP induction, followed by definitive locoregional treatment (resection and mediastinal dissection or radical radiotherapy).
Rapidly increasing data indicate that effectivesystemic therapy (induction chemotherapy), followed byradical local therapy, either resection with mediastinaldissection or radical radiotherapy, could be a bettertreatment option for these patients [6, 7]. An activeinduction chemotherapy regimen combining a high re-sponse rate with an acceptable toxicity is highly desiredin this setting. We previously described the results of chemotherapyusing vindesine-ifosfamide-platinum (VIP) in patientswith either locally advanced (unresectable) stage III orstage IV NSCLC [8]. Its activity, combined with its man-ageable toxicity profile, made it an attractive candidatefor induction chemotherapy. Compared to the North-American mitomycin-C-vindesine-platinum.
Demedts 1 2 the Leuven Lung Cancer Group 2 0 Department of Radiotherapy, University Hospital Gasthuisberg, Catholic University Leuven. Belgium 1 Department of Pulmonology (Respiratory Tumor Unit). 'Department of Thoracic Surgery 2 J. Vansteenkiste, MD. PhD Department of Pulmonology (Respiratory Tumor Unit) University Hospital Gasthuisberg Herestraat 49 B-3000 Leuven Belgium Summary Purpose: In the pioneer data from the Memorial-SloanKettering group, preoperative mitomycin-C-vindesine-platinum.
[Show abstract] [Hide abstract] ABSTRACT: In the pioneer data from the Memorial-Sloan-Kettering group, preoperative mitomycin-C-vindesine-platinum (MVP) induction chemotherapy in N2-NSCLC was accompanied with substantial pulmonary toxicity. In this study, the efficacy and toxicity of three-drug VIP induction chemotherapy, the pathologic response in resection specimens, the early survival and relapse patterns are examined.